<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01583920</url>
  </required_header>
  <id_info>
    <org_study_id>clinicaltrials_hchu_042012</org_study_id>
    <nct_id>NCT01583920</nct_id>
  </id_info>
  <brief_title>Focal Salvage HDR Brachytherapy for the Treatment of Prostate Cancer</brief_title>
  <official_title>Pilot Study of Focal Salvage HDR Prostate Brachytherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Association of Radiation Oncology</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiation therapy is considered a standard treatment option for the management of localized
      prostate cancer. Among the 20-30% who recur, a proportion of them will present with an
      isolated local recurrence, meaning no distant metastases. If left untreated, it may serve as
      a source for subsequent metastases. Salvage options available for isolated local recurrence
      include; temporary or permanent implantation of radioactive seeds into the prostate, complete
      removal of the prostate gland, use of low temperatures to treat the disease, and high
      frequency ultrasound to treat the disease. There are risks of complications associated with
      all these treatments, and there is presently no consensus as to which treatment is the best.
      Therefore, the aim of this pilot study is to look at the feasibility and toxicities of focal
      treatment of the prostate using temporary implantation of radioactive seeds into the prostate
      which the investigators hope will be less since the entire prostate is not treated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">July 2028</completion_date>
  <primary_completion_date type="Anticipated">July 2028</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of acute urinary and rectal toxicities</measure>
    <time_frame>Acute period (&lt;6 months)</time_frame>
    <description>Common Terminology Criteria for Adverse Events (CTCAE) v4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of late urinary and rectal toxicities</measure>
    <time_frame>Late period (&gt;6 months)</time_frame>
    <description>Common Terminology Criteria for Adverse Events (CTCAE) v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical (ie. prostate specific antigen) disease free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>5 years</time_frame>
    <description>Expanded Prostate Cancer Index Composite (EPIC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and late urinary toxicities</measure>
    <time_frame>5 years</time_frame>
    <description>American Urological Association Symptom Index Score (i.e. IPSS)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Focal salvage HDR prostate brachytherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>focal salvage HDR prostate brachytherapy</intervention_name>
    <description>Treatment will be delivered using 192-Ir HDR afterloading. Dose prescription is 2 fractions of 13.5 Gy each, delivered 1 week apart.</description>
    <arm_group_label>Focal salvage HDR prostate brachytherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy-confirmed locally recurrent prostate adenocarcinoma &gt; 30months after the
             completion of XRT, SBRT, LDR or HDR brachytherapy boost with XRT, or LDR or HDR
             brachytherapy as monotherapy by a stereotactic transperineal biopsy

          -  Staging T2-weighted, DWI and DCE-MRI that demonstrates solitary recurrence confined to
             prostate, and correlates with stereotactic transperineal biopsy

          -  Staging CT or MRI (abdomen and pelvis) and bone scan are negative for metastases

          -  American Urological Association Symptom Index Score (ie. IPSS) &lt; 15

          -  Baseline (post-XRT) serum PSA &lt; 10 ng/mL

          -  Prostate volume as measured by transrectal ultrasound (TRUS) &lt; 50cc

          -  ECOG performance status 0-1

        Exclusion Criteria:

          -  Any of the following prior therapies: transurethral resection of the prostate (TURP),
             radionuclide (permanent or temporary implantation) prostate brachytherapy,
             prostatectomy or prostatic cryosurgery, HIFU (high-intensity focused ultrasound),
             bilateral orchiectomy, chemotherapy for prostatic carcinoma

          -  Evidence of castrate resistance (defined as PSA &gt; 3 ng/mL while testosterone is &lt; 1.7
             nmol/L). Patients could have been on combined androgen blockade with initial
             radiotherapy but are excluded if this was started due to PSA progression.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Chung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre, Odette Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hans Chung, MD</last_name>
    <phone>(416) 480-6100</phone>
    <email>hans.chung@sunnybrook.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre, Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Chung, MD</last_name>
      <email>hans.chung@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Hans Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Loblaw, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerard Morton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Masoom Haider, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ananth Ravi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2012</study_first_submitted>
  <study_first_submitted_qc>April 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2012</study_first_posted>
  <last_update_submitted>February 16, 2018</last_update_submitted>
  <last_update_submitted_qc>February 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sunnybrook Health Sciences Centre</investigator_affiliation>
    <investigator_full_name>Dr. Hans Chung</investigator_full_name>
    <investigator_title>Dr. Hans Chung</investigator_title>
  </responsible_party>
  <keyword>prostatic neoplasms</keyword>
  <keyword>brachytherapy</keyword>
  <keyword>salvage therapy</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

